Crude Oil Gains Over 1%; VEON Shares Spike Higher US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%. Im...

#BIAF #Equities #IBG #IMMP #KLC #LOCO #Mid-Day #Market […]

[Original post on benzinga.com]

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis Immutep (NASDAQ: IMMP) announced on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study in first-line non-small cell lung cancer after a planned interim futility analysis.Enrollment will be halted, the study will be wound down with patient follow-up and site close-out, and Immutep says it is reviewing the data and next steps. The company now expects its cash runway to extend well beyond its prior guidance of Q2 CY2027 and will provide an updated outlook after operational assessments.

#IMMP TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

www.stocktitan.net/news/IMMP/tacti-004-phas...

Immutep Reports Encouraging Phase I Results for First-in-Class LAG-3 Agonist IMP761 Immutep Limited (Nasdaq: IMMP; ASX: IMM) announced positive findings from the Phase I study of IMP761, a first-in-class LAG-3 agonist antibody designed to treat

Immutep #IMMP Reports Encouraging Phase I Results for First-in-Class LAG-3 Agonist IMP761
prismmarketview.com/immutep-repo...

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study Immutep (NASDAQ: IMMP / ASX: IMM) reported a positive Phase I update for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.The single-ascending dose portion completed 2.5 mg/kg and 7 mg/kg cohorts with a favourable safety profile and no treatment-related adverse reactions beyond mild intensity. Dose-dependent immunosuppression was observed with significant, durable inhibition of three T-cell-mediated intradermal reactions at days 2, 9 and 23. The company said a PK/PD relationship was established between 1 and 7 mg/kg.The trial will continue as planned and additional updates, including a possible presentation at a major medical conference, are anticipated in 1H CY2026.

#IMMP Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

www.stocktitan.net/news/IMMP/immutep-announ...

$IMMP 🚀 TACTI-004 Phase III: 289 patients enrolled (38% of 756 target), 120+ sites active in 27 countries—US cleared! 📈 Futility analysis Q1 '26, full enrolment Q3 '26. Efti + Keytruda combo advancing NSCLC fight. Bulls takeover? 🔥 #Webull SS + 1D #IMMP #Biotech #Cancer NFA

x.com/i/status/200...

#IMMP Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

www.stocktitan.net/news/IMMP/immutep-announ...

Immutep Soars on Major Global Licensing Deal With Dr. Reddy’s Immutep Limited (Nasdaq: IMMP) gained almost 30 percent after announcing a major commercial partnership with Dr. Reddy’s Laboratories for eftilagimod alfa (ef

Immutep #IMMP soared after announcing that its first-in-class immunotherapy efti is heading into new global markets through a licensing deal with Dr. Reddy’s. prismmarketview.com/immutep-soar...

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa Immutep (ASX: IMM; NASDAQ: IMMP) and Dr. Reddy’s entered an exclusive licensing and collaboration for eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China, announced 8 December 2025. Immutep will receive an upfront payment of USD 20 million, is eligible for up to USD 349.5 million in regulatory and commercial milestones, and will receive double-digit royalties on sales in the licensed markets. Immutep retains rights in key markets (North America, Europe, Japan), holds global manufacturing rights, and will supply product to Dr. Reddy’s as efti advances in a registrational Phase III NSCLC trial (TACTI-004/KEYNOTE-F91).

#IMMP Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

www.stocktitan.net/news/IMMP/immutep-and-dr...

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue sarcoma subtypes including rare and highly aggressive tumours with poor prognosis Early translational data show a strong immune system activation inline

#IMMP Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

www.stocktitan.net/news/IMMP/translational-...

#IMMP Immutep Receives A$4.6 million R&D Tax Incentive from French Government

www.stocktitan.net/news/IMMP/immutep-receiv...

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p

#IMMP Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

www.stocktitan.net/news/IMMP/primary-endpoi...

Immutep Announces Successful Completion of FDA Project Optimus Requirements Immutep (NASDAQ: IMMP) announced the FDA has confirmed completion of Project Optimus requirements and agreed that 30mg is the optimal biological dose for eftilagimod alfa (efti). The dosing agreement is described as a major de-risking step for efti’s oncology programs and a building block toward potential future BLA filings. Immutep said the global TACTI-004 (KEYNOTE-F91) Phase III registrational trial in first-line advanced/metastatic NSCLC (efti + pembrolizumab + chemotherapy) is now in the process of opening clinical sites in the United States.

#IMMP Immutep Announces Successful Completion of FDA Project Optimus Requirements

www.stocktitan.net/news/IMMP/immutep-announ...

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer Immutep (NASDAQ: IMMP) announced that its registrational Phase III TACTI-004 (KEYNOTE-F91) trial in first-line advanced/metastatic non-small cell lung cancer has enrolled and randomised over 170 patients, exceeding the threshold required to trigger a futility analysis. The study now has more than 100 active sites across 24 countries. An independent data monitoring committee will assess futility using predefined criteria and a minimum 12-week follow-up, with the futility analysis on track for completion in Q1 CY2026. The announcement cites supportive prior data from TACTI-002 and INSIGHT-003 (combined >165 patients) reporting enhanced responses, PFS, and improved overall survival with efti plus pembrolizumab.

#IMMP Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

www.stocktitan.net/news/IMMP/immutep-announ...

50-Patient Phase II Trial: Immutep's Efti Takes on Early-Stage Breast Cancer with GW Cancer Center Phase II trial to evaluate efti as monotherapy and with chemotherapy in HR+/HER2-neg breast cancer. Study targets 50 patients, focuses on pathologic complete response in neoadjuvant setting.

#IMMP Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

www.stocktitan.net/news/IMMP/immutep-announ...

First-Ever Neoadjuvant Efti Combo Trial in Soft Tissue Sarcoma: Immutep to Present Phase II Results Phase II EFTISARC-NEO trial evaluating efti with KEYTRUDA and radiotherapy in soft tissue sarcoma to be presented at CTOS 2025. Study addresses 13,520 annual US cases.

#IMMP Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

www.stocktitan.net/news/IMMP/immutep-announ...

Judge Blocks Pillar of Trump’s Mass Deportation Campaign Judge Jia M. Cobb rejected what she called “a truly startling argument” from the government that it could use a fast-track procedure to remove people arrested far from the... @cosmicmeta.ai #ImmP

https://u2m.io/oVn0IENO

FDA Supports Immutep's Revolutionary First-Line Head & Neck Cancer Treatment Development FDA endorses development path for eftilagimod alfa in untreated head & neck cancer patients with low PD-L1. Learn about potential accelerated approval pathway.

#IMMP Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

www.stocktitan.net/news/IMMP/immutep-receiv...

Small-cap stocks in new uptrend with AROON Oscillator - #OBIO #PDFS #SPWH #TCBK #UPLD #WVE #ZNTL #ACCO #BORR #DEC #EAI #FF #KRP #PRO #QUAD #RIG #SES #NESR #MFIN #LGHL #KYTX #IMMP #FATE #EVAX #DAKT #BAND #AOB - More: crystalequityresearch.com/ieading-indi... - #smallcap

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 Immutep (NASDAQ: IMMP) announced the acceptance of three abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The presentations will showcase clinical trials of their first-in-class MHC Class II agonist, eftilagimod alfa (efti).The presentations include a Proffered Paper oral presentation on the EFTISARC-NEO Phase II trial in soft tissue sarcoma, a poster presentation on the INSIGHT-003 Phase I trial in first-line non-small cell lung cancer (NSCLC), and a Trials in Progress ePoster on the pivotal TACTI-004 Phase III trial in first-line NSCLC. The abstracts will be available on October 13, 2025.

#IMMP Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

www.stocktitan.net/news/IMMP/immutep-announ...

#IMMP is tackling autoimmune diseases at the source. New Phase 1 data show 80% T cell suppression with no safety issues for its first-in-class LAG-3 agonist IMP761.
#Immutep
prismmarketview.com/early-data-f...

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases Immutep (NASDAQ: IMMP) reported positive initial efficacy data from its Phase I study of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The placebo-controlled, double-blind study demonstrated significant T cell suppression with 80% inhibition at 0.9 mg/kg dosing level and showed a favorable safety profile with no treatment-related adverse events. The company is proceeding with higher single ascending dose levels of 2.5, 7, and 14 mg/kg. IMP761 is designed to treat autoimmune diseases like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis by enhancing LAG-3's brake function to silence dysregulated self-antigen-specific memory T cells. The trial is being conducted at CHDR in Leiden, Netherlands, with additional data expected in the second half of 2025.

#IMMP Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

www.stocktitan.net/news/IMMP/immutep-announ...

Small-cap stocks with declining money flow, Tue Jun 3rd - #YGMZ #SRBK #NTCL #WIMI #TRAW #SOHU #MPB #LX #IMMP #ETCN #CTRM #ASTH #QD #PX #PBT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breakthrough: Immutep's Triple Therapy Shows 3X Better Results in Rare Cancer Treatment Trial Novel cancer treatment combo achieves 50% tumor reduction vs 15% historical data in soft tissue sarcoma. See detailed efficacy data from this breakthrough study.

#IMMP Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

www.stocktitan.net/news/IMMP/immutep-s-efti...

Breakthrough Lung Cancer Treatment Achieves 61% Response Rate, Outperforms Standard Therapy by 27% New triple combination therapy shows remarkable 90.2% disease control rate in advanced lung cancer patients. See detailed efficacy data across PD-L1 expression levels.

#IMMP Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

www.stocktitan.net/news/IMMP/immutep-s-efti...

Small-cap stocks with strong volume gains, Mon May 5th - #ZCAR #UCAR #KWE #KDLY #IVF #FMST #STEC #SBET #QNCX #NCNA #MRIN #IMMP #FNGR #CTRM #BCRX #AIFF #VCSA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 Immutep (NASDAQ: IMMP) has announced exceptional results from its TACTI-003 Phase IIb trial, showing a median Overall Survival (OS) of 17.6 months for head and neck cancer patients with PD-L1 CPS &lt;1. The trial evaluated eftilagimod alfa (efti) combined with KEYTRUDA® in first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. The results significantly outperform current standard-of-care treatments, which show OS of 10.7 months for cetuximab + chemotherapy and 11.3 months for anti-PD-1 therapy + chemotherapy. The combination therapy was well-tolerated with no new safety concerns. Notably, this represents a potential breakthrough for the 20% of patients with CPS &lt;1, who currently have no chemotherapy-free treatment options. The company has requested an FDA meeting to discuss potential paths to approval, leveraging its Fast Track designation in 1L HNSCC.

#IMMP Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

www.stocktitan.net/news/IMMP/immutep-s-efti...

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Immutep (NASDAQ: IMMP) has initiated its pivotal TACTI-004 Phase III trial with the first patient successfully dosed at Calvary Mater Newcastle Hospital in Australia. The trial will evaluate eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with KEYTRUDA® and chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC).The global study will enroll approximately 756 patients across more than 150 clinical sites. The trial has received regulatory approvals in 16 countries, including Australia, Canada, and several European nations, with additional clearances expected soon. The 30mg subcutaneous efti dosing will be used, based on previous regulatory discussions and demonstrated efficacy.NSCLC represents 80-85% of all lung cancer diagnoses, with less than 30% survival rate after five years. The trial results will support a potential marketing approval application in NSCLC, one of the largest oncology indications.

#IMMP First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

www.stocktitan.net/news/IMMP/first-patient-...

Immutep's Cancer Trial Shows Triple Therapy Boosts Tumor Response Rate by 233% in Sarcoma Study Immutep's Phase II EFTISARC-NEO trial reports 50% tumor response with efti + KEYTRUDA + radiotherapy combo, tripling standard care outcomes. Full enrollment reached, safety confirmed.

#IMMP Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

www.stocktitan.net/news/IMMP/patient-enrolm...

Immutep's Lung Cancer Trial Shows Breakthrough 81% Survival Rate in INSIGHT-003 Study Immutep completes enrollment for INSIGHT-003 trial, reporting exceptional 32.9-month median survival in non-small cell lung cancer patients with novel triple combination therapy.

#IMMP Patient Enrolment Completed for INSIGHT-003

www.stocktitan.net/news/IMMP/patient-enrolm...

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Immutep (NASDAQ: IMMP) has reported positive initial safety data from its Phase I trial of IMP761, the world's first LAG-3 agonist antibody. Through the first three of five single ascending dose cohorts in healthy participants, no treatment-related adverse events have been observed. The placebo-controlled, double-blind study is being conducted at the Centre for Human Drug Research in Leiden, Netherlands, involving up to 49 participants.IMP761 is designed to treat autoimmune diseases by enhancing LAG-3's 'brake' function on T cells to restore immune system balance. Additional safety data and pharmacokinetic/pharmacodynamic relationships assessment are expected in the first half of 2025. The drug shows potential for treating conditions like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.

#IMMP Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

www.stocktitan.net/news/IMMP/immutep-announ...